MedAnnex announces £11.5 million equity investment, led by Morningside Ventures

MedAnnex is excited to announce a £11.5 million equity investment led by Morningside Ventures, a major investor in the global Life Sciences sector. The funds will be used in conjunction with recent grant awards from Innovate UK and Scottish Enterprise to accelerate MedAnnex’s research and development activities. In collaboration with experts at a number of academic institutions including UCL, Glasgow University and Anglia Ruskin University, MedAnnex is developing therapeutic antibodies with the potential to treat a range of diseases. Christopher Wood, Chairman said: “This is a significant advance for MedAnnex and recognition of the groundbreaking work that has been accomplished to date. The investment will allow the company to capitalise further on its position as a leading Scottish biotechnology company developing innovative approaches to treating autoimmune diseases and other medical conditions”. We are also delighted to welcome Isaac Cheng to the MedAnnex Board as a Morningside representative. Osborne Clark provided legal representation.

 

For more information, please visit: https://medannex.org/